BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that four abstracts summarizing data from the Company’s Phase 3 studies of GATTEX™ (teduglutide) in patients with short bowel syndrome (SBS) were selected for oral presentations at the 16th United European Gastroenterology Week (UEGW) meeting in Vienna, Austria, October 18-22, 2008, including a presentation of 52-week data from the Phase 3 study of GATTEX in SBS patients. The UEGW is the largest gastroenterology meeting in Europe.
